Introduction
F11Risthe name of agene encoding aprotein called the F11 receptor,a lso known by the name junctionala dhesion molecule (JAM-A). This protein wasidentified first as aduplexofproteins constitutively expressed on the surfaceo fh uman platelets (1) . Stimulation of F11R/JAM-A caused platelet activation in aprocess involving the followingevents: F11R/JAM-A dimerization (2) ,phosphorylation by activatedPKC associated withtransient (reversible) translocation of PKC isoenzymes α and ζ ,and lasting translocation of PKC isoenzymes δ , β ,n', and θ (3), complex formation of F11R/JAM-A with the integrin GPIIIa (2) and activation of the Fcγ RIIp athway (4) . Theu tilization of specific F11R/JAM-A peptidea ntagonists and recombinant proteins (5-7) has begun to reveal the roleofF11R/JAM-A in the process of plateletadhesion to inflamedendothelial cells and identified F11R/JAM-A as ap otentiallyi mportant moleculei np latelet plaque formation leading to inflammatorythrombosis and atherosclerosis, with platelets as critical factorsinvolved in the progression and development of cardiovasculard isease ( 8) . Promoter analysis of the humanF11R gene has revealed the presence of an NF-kappaB (NF-κ B) consensus sequence, thus furtherimplicating F11R'srole in inflammatoryprocesses (9) .
Enhanced expression and dynamic redistribution of cell adhesion molecules( CAMs) such as intercellular adhesion molecule( ICAM), vascularc ella dhesion molecule-1 (VCAM-1), and platelete ndothelial adhesion molecule-1 (PECAM-1/CD31),a ll members of the immunoglobulin superfamily, occur in the endothelium in response to cytokines (10, 11) . Expression and localization of CAMs at the luminal surfaceofatherosclerotic lesionsimplicates their participation in the pathology of atherosclerosis (12) (13) (14) (15) with ICAM-1,V CAM-1a nd PECAM-1 levels modulatedwithin the lesioned vasculature of the atherosclerosis-prone apoE -/-mousemodel (15) .
Similartothese CAMs, F11R/JAM-A is acelladhesion molecule and member of the immunoglobulin superfamily ( 16) whose important role in thrombosis and atherosclerosis is being exploredb yusand other laboratories. The combined treatment of EC with inflammatorycytokines tumor necrosis factor-alpha (TNFα) and interferon-gamma( INFγ) resultedi nar edistribution of F11R/JAM-Afrom intercellular junctions to the cellsurface of the inflamedE C ( 17) . An enhancede xpression of F11R/JAM-A wasevident already in the earlystagesofatherosclerosis in the endothelium of apoE-deficient micef ed with high-fat diet (18) , and the solubleformofF11R/JAM-A significantly reduced mononuclear cellrecruitment to ex vivo perfused atherosclerotic carotid arteries (18) . TheF11R gene is located in ac ritical region on chromosome1 q21-23 (F11R-USF1), ar egion thati ss ignificantly linked to coronaryh eartd iseasea nd familial-combined hyperlipidemia (19) .This finding also suggests that the F11R/JAM-A protein has proatherogenicpropertiespredicted in its involvement in pathophysiological processes underlying cardiovasculardiseases (5, 6) . Furthermore, the approximate two-foldu pregulation of F11R/JAM-A shown to occur in unstable versuss tabler egions of the atherosclerotic plaque (20) , expands the role of F11R/JAM-A to include its involvement in the rupture of the atherosclerotic plaque as well.
In the present study,weconductedexperiments in culture and in vivo designedtotestthe suggestion that the interaction of the newly-expressed F11R/JAM-A sites on the surfaceofcytokineinflamedE Cw ith the constitutively-expressed F11R/JAM-A sites on thesurfaceofcirculating platelets plays acausal role in the adhesion of platelets to the inflamedendothelium.
Materials andmethods

Human endothelialcells
Human aortic( HAEC)a nd umbilicalv eine ndothelial cells (HUVEC) (10 6 )(Cascade Biologics, Inc.,P ortland,OR, USA), were growni nM edium 200c ontaining 1% or 2% fetal calf serum (FCS), respectively.Atsecondpassage,both HUVEC and HAECw ere treated with purifiedh uman recombinant TNFα (100u nits/ml)( R&D Systems, Inc., Minneapolis, MN,U SA), vascularendothelial growth factor (VEGF;10ng/ml)(R&D Systems) and INFγ (200units/ml)(Roche Diagnostics, Mannheim, Germany) for 24 hours (h) at 37 o C. Theprocedures involving the adhesion of platelets to endothelialc ells were followeda sd escribed (6) .
Human platelets
Platelets were isolatedasdescribed (1) . Collagen (nativetype 1), used as the agonist, waspurchasedfrom Chrono-logCorp. (Havertown, PA ,USA).
F11R/JAM reagents
Monoclonalantibody F11 (M.Ab.F11; human F11R/JAM antibody), developedi no ur laboratorya gainst the humanp latelet F11R(1), wasobtained from BD PharMingen (San Diego, CA, USA). JAM-1 polyclonala ntibody wasp urchasedf rom R&D Systems. HumanF 11R recombinant protein wasg enerated as described (6, 7) . TheF11R peptides were synthesized and purified (95%)byNew England Peptide, Inc.(Gardner,MA, USA). vWF antibodyw as obtainedfrom Chemicon International(Temecula, CA,USA).
To tal RNAisolation
TotalRNA wasextractedfrom the isolatedaorta of apoE -/-and control C57BL/6J mice utilizing TriZol( Invitrogen, Carlsbad, CA,USA). ApoEknockout mice (apoE -/-)with C57BL/6J back- ground of 12 weeks of age and control age-matchedw ild-type C57BL/6J mice, obtainedfrom JacksonLabs (Bar Harbor,MA, USA), were fed aregular mouse chowdiet. All procedures were conducted in accordance with the SUNYD ownstate Institutional Guidelines for Animal Use and Care. Controls:Specimens of renal arteryand aorta were obtained within12hofdeathfrom young cadaverickidneytransplant donors immediatelyatthe timeoforgan harvesting fortransplantation and used as controls (3 males, 23 to 38 years old).Inaddition to these cadavericcontrol specimens, experiments detailed in Figure 3C utilizedp laque-free specimens obtainedf rom the aorta of the same patient and were used as internal controls .
All protocolswere approvedbythe SUNY Downstate Institutional ReviewBoardCommittee. All patients signed appropriate informed consent forms prior to the surgicalexcision of the atherosclerotic material. 
Statisticalanalysis
The data were analyzed by Student's t-test and the non-parametricMann-WhitneyU-test.Differences were considered significant at P<0.05.
Histology, immunofluorescence and confocal microscopy
Human specimens of atherosclerotic plaque were subjected to standard tissue processing and staining with hematoxylin and eosin (H&E) (21, 22) . Pretreatedparaffin-embeddedhuman arterial segmentswere deparaffinizedand prepared for immunostaining with primaryr abbit polyclonala nti-human vonW illebrand Factor (vWF;C hemicon International, Temecula, CA, USA) or murinemonoclonalanti-human F11R antibodies, Secondaryantibodies consisting of Alexa Fluor 568 conjugatedgoat anti-rabbit IgG (red color)orFITC-conjugated goat anti-mouse IgG (green color) were mountedwith ProLong RGold anti-fade reagent (Molecular Probes, Eugene, OR, USA) followedb y examination by confocal scanning lasermicroscopy.
Human umbilical vein endothelialcells (HUVEC), grownon coverslips in completegrowthmedia(2% FBS), were exposed to cytokines for24hat 37°C, incubated for1.5 hwith murine antihumanF 11R M.Ab.F11 (25 µg/ml)o rg oat anti-murine JAM polyclonala ntibody (15 µg/ml), fixedi np araformaldehyde (4%), labeledwith goatanti-mouse Ig (1:200) or rabbit anti-goat (1:100) FITC conjugated secondarya ntibodies, and mounted with ProLong RGold.
Slides of paraffintissue containing cross-sectionalslices of the proximalaorta of mice were processed for deparaffinization, incubated with M.Ab.F11 or goat anti-mouse JAM-1 polyclonal antibody, labeledw ith secondaryF ITC conjugated antibodies, and mountedwith Prolong Gold anti-fade reagent.
The BioradMRC 1024ES confocal microscopysystem was used to generate fluorescent images. CulturedH UVEC (passages 1-3 ), grownt oc onfluencyo ng lass coverslips, were treated with purifiedh uman recombinant TNFα ,v ascular endothelialg rowthf actor (VEGF)( R&D Systems), and INFγ (Roche Diagnostics).HUVEC were fixedwith 1% paraformaldehyde at 27°C, 10 min,i ncubated with M.Ab.F11 for 1ha t 37°C, followedbyincubation with FITC conjugatedsecondary antibodiesfor 1h.Carbocyanine monomerTO-PRO-3 wasused for nuclear staining (Molecular Probes).
Results
Studies of Apo E-deficientmice
At three months of age, apoE -/--deficient micedemonstrate the presence of well-developedplaquesalong their vasculature.As shown in Figure 1A , the aorta of apoE -/-mice demonstrated asignificantly-enhanced expression of F11R mRNA in the proximal aortae( lane 2),a sc ompared to the barely-detectable levels of F11R mRNAmeasured in controls (lane 1). Quantitative confirmation of these findings wasprovided by conducting real-time RT-PCR, and as shown in Figure 1B ,the levelofF11R mRNA in the aorta of the apoE -/-micew as two-foldgreater thanthat observedi nw ild-type mice. Immunofluorescence of identical specimens utilizing F11R specifica ntibodies revealed intense staining of the F11R protein in the proximalaorta of apoE -/-mice ( Fig. 2B ) whichf ollowedt he exact contoursd isplayedb yt he atherosclerotic region; low, background staining wasobservedin the aorta of wild-typemice( Fig. 2A) .Amagnifiedviewofapor- ( Fig. 2C) demonstrates the highlyo ver-expressed F11R protein found within the plaque of these atherosclerotic-prone animals.
Studies of human subjects
In parallels tudies,F 11R mRNAl evels were measuredi ne ndarterectomy specimensofarteries from atheroscleroticpatients. Figure 3A showsthatF11R levels were found to be significantly higherinthe lesionedregionsofsix of the sevenpatients examined than in control specimen,obtainedfrom cadaveric kidneydonors. Afive-fold increaseinthe overall levelofF11R mRNAwas demonstratedi nt he plaqueso fa therosclerotic arteries as compared to controls (Fig. 3B) . In addition, we compared thelevel of F11R mRNAwith plaquecontent in segments, obtainedfrom the same aorta, that were identifiedasplaque-free,incomparisonto plaque-containing regions. As showninFigure 3C,regionsidentifiedtocontain high levels of atherosclerotic plaques (bars 3and 4) were found to exhibits ignificantlyh igher levels of F11R mRNA than twop laque-free segments obtainedf rom the same aorta of this patient (bars 1a nd 2). Histologicale xaminations conductedt od emonstrate thep resenceo ft he atherosclerotic plaque revealed that approximately80% of the lumen of the carotidofpatient5was obstructedbythe plaque (Fig. 4A) , andupon closerinspection (Fig. 4B) consistedofalipid-laden core with infiltrating cells,connective tissueelements and foam cells.Immunofluoresence stainingo ft he atherosclerotica orta of the same patient revealed ahigh levelofstaining of F11R throughoutthe entire specimen (Fig. 5A) . Staining for vWFinthe same specimen demonstratedt he presenceo ft he atherosclerotice ndothelium (Fig. 5B) . The merged image, showninFigure 5C,depicts the significantd istributiono ft he F11R protein throughout the plaque as it is surroundedbythe atheroscleroticendothelium, as shownbythe endothelial marker, vWF. In contrast, control specimen of the aortao btainedf rom cadaveric transplant donors, identified as plaque-free, showed theF11R stainingonlywithin the endothelium (Fig. 5D) . Stainingf or vWFd emonstrated its presencealsowithin the endothelium of the control aortic specimen (Fig. 5E) . The merged immunofluoresenceimage of the controla orta (Fig. 5F )d epictsc o-localization of the F11R/JAM-A protein andvWF togetherwithin the endothelium of the aorta.
Investigationsofhuman endothelialcells in culture
In studiesdesignedtodetermine the potentialcauses of the increased levels of F11R in atherosclerotic plaqueso bserved in vivo,weexamined the effects of the treatment of EC with inflammatorycytokines on the interactions betweenplatelets and EC. In previousstudiesweexposed human EC to onlyasingle type of cytokine. However, acombined cytokinetreatment is known to causeanevengreater redistribution of the F11R from tight junctions to the luminals urfaceo fE C. Therefore, in the present study,our experiments specificallyfocusedonthe exposure of EC to ac ombination treatment using the cytokines TNF α and INFγ .Asshown in Figure 6 , the simultaneous addition of both cytokines to cultured humanaortic EC (HAEC) resulted in significant upregulation of F11R mRNA thatr emained significantly elevatedf or 24 hf ollowing the initial application of the cytokines.S imilart oa ortic cells,H UVEC alsod emonstrated significantlyincreased levels of F11R mRNAwith time following the simultaneous addition of both cytokines (Fig. 7) ,a lthough differences in sensitivity to the cytokines between these twocelltypes were observed. Differencesinsensitivity to cytokine stimulation between aortic endothelialc ells and HUVEC could not be explained by different passages, as the same cell passage wasutilized forboth cell types in these experiments.
Immunofluoresencestaining of non-treated HUVECrevealed the presence of F11Rwithin the plasma membranes of these cells (Fig. 8A) ; counterstaining with anuclear stain revealed the HUVECnuclei (Fig. 8B) . The merged image shown in Figure 8C demonstrates the association of F11R onlyw ith plasma membranes;t he clear regions of the HUVEC cytoplasm depictt he lackofstaining for F11Runder these control conditions. Such merged images were utilized to analyze changes in F11R immunofluorescence caused by the treatment of confluentH UVEC cultures withthe combination of cytokines.Asshown in Figure  9 , such simultaneous cytokinet reatment caused substantial changes in the localization of F11R. In comparisontothe nontreatedHUVEC (Fig.9A) , thetreatment of HUVECwith the cytokines TNF α plus INF γ for 24 hresultedinadecreased intensity for F11Rstaining at membrane intercellular junctions.Asshown in Figure 9B ,f ollowing the combined cytokinet reatment of HUVEC, the F11Rprotein becameevenlydistributedthroughout the entire cell body of the HUVEC rather than concentrated withintight junctions.
Investigationsofplatelet adhesiontoECinculture
To examine the contribution of F11R to the force of adhesion operating between plateletsa nd inflamede ndothelial cells, we examinedt he effects of specific F11R-inhibitors on the adhesion of platelets to HUVEC treateds imultaneously with cytokines TNF α plus INF γ .W eh avep reviouslyr eported that peptides designated F11R-peptide-1 (amino acid sequence 28 The participation of F11R wasmonitored further under conditions in whichcytokine-treatedHUVEC were reacted with activatedp latelets. Undert hese conditions, HUVEC were pretreated with TNF α and INFγ ,whereashuman platelets were activatedbyexposure to collagen (Fig. 10B) . We determinedthat approximately 14.8 ±2.49 X10 5 of collagen-activatedplatelets bound to 1X10 4 of the TNFα -plus INFγ -treated HUVEC(control bar, Fig. 10B ). The presenceo ft he soluble recombinant F11R protein (sF11R;10µg/ml)significantly inhibitedthe adhesion of activatedp latelets to TNF α -p lus INFγ -treated HUVEC. Furthermore,the presenceofF11R peptide 1resulted in significant inhibition of plateleta dhesion to the inflamed HUVEC as didthe presenceofF11R peptide 4. In contrast, the addition of ap eptide whose sequence of amino acids corresponded to F11R peptide 1but wasscrambled by random insertion of amino acids during the synthesis of this peptide (scrambled peptide 1) did not inhibit the adhesion of activated platelets to the cytokine-treated HUVEC.Finally, we monitored the effect of F11Rinthe adhesion of platelets to HUVEC treated for 24 hw ith the growth factor VEGF (10n g/ml). Figure 10C demonstrates that, whereas 10.4 ±1.7 X10 5 collagen-activated platelets adheredt o1X1 0 4 VEGF-treated HUVEC (control bar); thepresence of sF11R(1.5-3.0 µ g/ml)resultedinthe inhibition (byabout 35% and 50%, respectively)ofthe adhesion of collagen-activatedplatelets to the VEGF-treated EC.
Discussion
Recent studieshavedemonstrated thatplatelets adhere to an inflamed endothelium even prior to the invasion of leukocytesand before lesions become detectable, suggesting thatthis adhesion is an initial step in the development of plaquesinatherosclerosis (23) (24) (25) . Theresults of the studyreported hereprovide newinsightsi nto the molecularm echanisms by whichi nflammatory agents initiate the interaction of platelets with endothelialcells, leading to formation of thrombotic plaques. Undern ormal physiological conditions,endothelial cells (EC) arenon-thrombogenic (26-28).H owever,t he non-thrombotic surfaceo fE C can be transformed to ap rothrombotic surface followingt heir exposure to inflammatoryagents, resulting in procoagulant activity and predisposition to thrombosis (28) (29) (30) .Previousstudies of the adhesion, accumulation and recruitment of platelets onto the inflamedsurfaceofcytokine-stimulatedEChaveimplicated P-selectin (24, 31) , the P-selectin glycoprotein ligand (PSGL-1) (31, 32) , platelete ndothelial cell adhesion molecule-1 (PECAM-1) (33 -35), beta-1 integrin (30, 31, 36, 37) , tissue factor (29) , vonWillebrand factor (24, 30) , and GPIIb/IIIa (31)in this process. Recently,t he F11R/JAM-A protein has beend escribedwith propertiesindicating its potential role in triggering the pathogenesis of inflammatorythrombosis and atherosclerosis (6) .The purpose of the study reported herewas to provide additionalevidencefor this role.
The results reported here demonstrate that upregulation of F11RmRNAisinducedbycytokines in EC both from venal and arterial vessels, and thatt he newly-induced F11R/JAM-A protein has asignificant role in the adhesion of platelets to the inflamed endothelium. Thecombined cytokinetreatment utilized in the present study wasc ritical fort he induction of maximal changes in the redistribution of F11R/JAM-A to the vessel lumen. Therefore, these experimental conditions aremost optimal for examining the roleofF11R/JAM-A in plateletadhesion to EC under inflammatoryconditions, that areknown to involve the action of both TNF α and INFγ (38) . Experiments utilizing specificF 11R/JAM-A inhibitors determined thato ver5 0% of the force of plateleta dhesion to EC inflamedb ye xposure to [TNF α +I NFγ] is exertedb yF 11R/JAM-A.W ec onclude that F11R/JAM-A-mediated adhesion of platelets to EC is acritical event in the inflammatoryp rocesst hat leads to thrombosis in non-denuded vessels. We propose that circulating platelets, whichconstitutively express the F11R/JAM-A molecule on their surface(1) adhere directlytothe inflamed endothelium by virtue of their ability to interact with F11R/JAM-A moleculesthat are newlye xpressed on the exposed surfaceo fi nflamed EC. This homologous interaction (6) could cause the initial adhesion of platelets to endothelial cells in an earlystage,thus triggering the process of inflammation-induceda therogenesis. Figure 11 depicts aschematic presentation of the proposedsteps of this process, whichisinitiatedbythe activation of the transcription factor NF-κ BinECbycytokines, followedbythe interaction of this transcription factor with specificb indings egments for NF-κ B present in the promoter region of the F11R gene (9) .This sequenceofevents is consistent with the reports that platelets adheret ot he inflamede ndothelium even prior to the invasion of leucocytes and the detection of lesions (23) (24) (25) . Platelet thrombi arethen stabilizedalso by other CAMs and integrins (24, (29) (30) (31) (32) (33) (34) (35) (36) (37) aref ormed and leadt ot he development of atherosclerotic lesionsand atherothrombosis (23) .Figure11also serves to point out specific moleculare vents, to be studied in vivo under flow conditions,inorder to provide final proof for the role of F11R in initiating and/or promoting atherogenesis and atherosclerosis.
In parallel experiments of the study reported here, we have begun to examine the involvement of F11R/JAM-A in the formation of atherosclerotic plaques in vivo.Inthe first of these experiments we demonstrated ahighlyenhanced expression of F11R/JAM-A in the aorta of 12-week-old apoE -/-mice, an advancedage in whichatherosclerotic plaquesare well established (39) . Theexpression of F11R/JAM-A on the atherosclerotic endothelium of carotid arteries of apoE -/-wasobservedpreviously by others (18) . However, these animals were studiedatanearlier stageofdevelopment (6 weeks)and fedanatherogenic dietwith ahigh fatcontent. Since the mice in our study were maintained on aregular chowdietwithoutahigh-fat content, we conclude thatthe advancing age of these animals is causing aspontaneous upregulation of F11R mRNA-transcripts and induction of F11R/JAM-A protein expression in cellular components of the plaquesdeveloping in these animals.
Similar to the results with apoE -/-mice, oure xamination of F11R/JAM-A expression in plaquesdeveloped in vivo in the arteries of atherosclerotic humanp atients revealed abnormallyhigh levels of F11R/JAM-A mRNAand F11R/JAM-A protein. A recent study (20) of forty-six human atherosclerotic patients reported of enhancedexpression of F11R/JAM-A in areasofinstability of the atherosclerotic plaque,which areassociatedwith the rupture of plaquesand with embolic complications that canlead to myocardialinfarcts and/or occlusions in the cerebralvasculature. Theresults of the in-vivo studieswith animals and human patients areconsistent with the in-vitro data on the criticalrole of F11R/JAM-A in the initial adhesion of platelets to inflamedEC. Thus,t he sequence and structureo ft he peptides and recombinant protein whichspecificallyantagonize the action of F11R canprovide the basis for the design of noveldrugs for the prevention and treatment of atherosclerosis, thrombosis, heart attacks and stroke.
